Helixmith Obtains Japanese Patent for CAR-T Cell Therapy Technology

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 17th that it has obtained a Japanese patent for CAR-T cell therapy technology targeting the TAG-72 antigen. The patent pertains to cells and compositions expressing 'ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS.'

This is an adoptive cell therapy for cancers expressing the sialyl Tn antigen (STn) on the TAG-72 (Tumor Associated Glycoprotein 72) glycoprotein, which is highly expressed in solid tumors. TAG-72 is a tumor marker consisting of a protein and carbohydrate complex found on the surface of cancer cells.

Helixmith developed 'anti-STn CAR-T cells' that specifically recognize the STn antigen and confirmed their anti-tumor effects against cancer cells expressing the STn antigen on the TAG-72 glycoprotein.

The cancers treatable with 'anti-STn CAR-T cells' include all cancers expressing TAG-72. Cancers expressing TAG-72 include various solid tumors such as colorectal cancer, ovarian cancer, gastric cancer, breast cancer, esophageal cancer, bladder cancer, lung cancer, and pancreatic cancer, and are expected to be applicable as treatments for a wide range of cancers.

Seungshin Yoo, CEO of Helixmith, said, "CAR-T cell therapies are called miracle anticancer drugs and fourth-generation anticancer drugs, and are gene therapies receiving worldwide attention. Obtaining this Japanese patent is highly significant," adding, "Based on this patent, we expect the development of anticancer gene cell therapies for cancers expressing TAG-72."

This content was produced with the assistance of AI translation services.